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Abstract
Background Malnutrition, weight loss, and muscle wasting are common in patients with foregut cancers (oesophagus,
stomach, pancreas, liver, and bile ducts) and are associated with adverse clinical outcomes. However, little is known about
the changes in body composition that occur in these patients during chemotherapy and its impacts clinical outcomes.
Patients and methods A prospective study of adult foregut cancer patients undergoing chemotherapy between 2012 and
2016 was conducted. Computed tomography images were evaluated for cross-sectional skeletal muscle area (SMA) and
adipose tissue area (ATA) at two time points [interval 118 days (IQR 92–58 days)]. Longitudinal changes in SMA and ATA were
examined using paired t-tests. Sarcopenia and low muscle attenuation (MA) were deﬁned using published cut-points. Cox pro-
portional hazards models were used to estimate mortality hazard ratios for key predictors.
Results A total of 225 foregut cancer patients were included (67% male, median age 66 years). At baseline, 40% were
sarcopenic, 49% had low MA, and 62% had cancer cachexia. Longitudinal analysis (n = 163) revealed signiﬁcant reductions
in SMA [6.1 cm2 (3.9%)/100 days, P < 0.001]. Patients treated with neoadjuvant chemotherapy experienced greater losses
in SMA and skeletal muscle mass compared with patients receiving palliative chemotherapy [6.6 cm2 (95%, conﬁdence
interval, CI: 10.2 to 3.1), P < 0.001 and 1.2 kg (95% CI: 1.8 to 0.5), P < 0.001, respectively]. Neither sarcopenia
nor low MA at baseline was associated with reduced survival. A loss of SMA >6.0%/100 days (highest fourth) independently
predicted overall survival in patients receiving palliative chemotherapy [hazard ratio: 2.66, (95% CI: 1.42 to 4.97), P = 0.002].
Conclusions Patients with foregut cancers, particularly those treated with neoadjuvant chemotherapy, experience signiﬁcant
losses of muscle during chemotherapy. A high level of SMA loss is prognostic of reduced survival in patients treated with
palliative chemotherapy. Multimodal interventions to stabilize or increase muscle mass and inﬂuence outcome warrant further
investigation.
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Introduction
Cancers of the foregut (oesophagus, stomach, pancreas, liver,
and bile ducts), collectively account for over 350 000 cancer di-
agnoses in Europe annually. The 5 year survival remains low;
11% in oesophageal, 25% in stomach, and 6% in pancreatic
cancer,1 and they are historically associated with high rates
of malnutrition that adversely effects clinical outcome.2–4
Cancer cachexia (CC) is a multifactorial syndrome that is
characterized by the loss of muscle with or without the loss
of fat mass leading to progressive functional impairment.5
The syndrome encompasses involuntary weight loss,
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anorexia, a low body mass index (BMI), systemic inﬂamma-
tion, metabolic changes, and/or low skeletal muscle mass
(sarcopenia).5 Recent studies have shown that sarcopenia
[assessed using computed tomography (CT) images] is com-
mon in foregut cancers with rates reported to be >40% in
the setting of local6,7 and advanced disease.8,9 Sarcopenia is
associated with physical disability,10 increased length of hos-
pital stay,11–13 post-operative infections,12 poorer tolerance
to chemotherapy,7,14 and reduced survival.15 However, no
consistent association between sarcopenia and reduced sur-
vival has been demonstrated in foregut cancers.7,8,16 CT im-
ages provide not only a quantitative measure but also a
qualitative measure of skeletal muscle. Muscle radiation at-
tenuation is a radiological characteristic, and skeletal muscle
with a low radiation attenuation is reﬂective of intramuscular
adipose tissue inﬁltration and poor ‘quality’ skeletal mus-
cle.17 Importantly, low muscle attenuation (MA) is emerging
as an important predictor of clinical outcome in patients with
cancer and, in some instances, a stronger predictor of survival
compared with muscle mass alone.15,18–20
The precision associated with CT analysis of body composi-
tion has allowed recent investigations to focus on the nature
and magnitude of changes in body composition during the
disease trajectory in patients with cancer. However, these
studies are typically retrospective with small sample sizes
ranging from 35 to 65 patients6,9,16,21–25 and very few larger
studies exist (n > 100).26–28
Loss of muscle during anticancer treatment has been
shown to be prognostic of reduced survival in ovarian,28 colo-
rectal,21,26 and pancreatic cancer patients;22 however, this
has not been consistently demonstrated, and no effect was
observed in gastro-oesophageal and pancreatic cancer pa-
tients.6,25 To our knowledge, larger studies evaluating the
prevalence and signiﬁcance of altered body composition that
may occur in patients with foregut cancers undergoing stan-
dard chemotherapy are lacking.
The primary aim of this prospective study was to examine
the longitudinal changes in body composition parameters
using single slice CT images in foregut cancer patients under-
going chemotherapy and to determine if these changes had a
prognostic impact on overall survival.
Methods
Study population
Adult patients (>18 years of age), with a solid malignancy of
the foregut presenting for chemotherapy, were eligible to
partake in this prospective observational study. All eligible
patients were approached by a member of the research team
(L. D., E. N. B., and S. C.), and data were collected from pa-
tients who provided informed written consent between June
2012 and September 2016. Subjects were admitted for che-
motherapy to one of two university teaching hospitals in Cork
City serving a catchment population of 870 000. Cork Univer-
sity Hospital is the regional cancer centre, and Mercy Univer-
sity Hospital is a satellite cancer centre as per the National
Cancer Control Program. Both hospitals provide inpatient,
day patient, and outpatient services along with a 24/7 emer-
gency department. Mercy University Hospital is the specialist
hospital for the surgical management of hepato-
pancreaticobiliary (HPB) and upper gastrointestinal cancers.
Both hospitals have dedicated medical oncology wards, and
Cork University Hospital is the regional centre for radiation
oncology and is a level 1 trauma centre. The local ethics com-
mittee granted ethical approval for this study, and the study
was performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments.
Patient information recorded
On assessment, patient’s weight, height, and BMI were re-
corded [weight (kg)/height (m2)]. BMI was classiﬁed
according to WHO classiﬁcations of BMI. CC was deﬁned
based on the international consensus deﬁnition.5 Clinical
and pathological data were collected during medical chart re-
view and included information on patient demographics (age
and gender), performance status (the Eastern Oncology
Cooperative Group performance status), primary tumour site,
stage and extent of metastatic disease (if present), oncologi-
cal treatment, and type of chemotherapy. Cancer diagnoses
were grouped and included gastro-oesophageal and HPB can-
cers (pancreatic, gallbladder, liver, and bile ducts). Response
to chemotherapy was evaluated according to the response
evaluation criteria in solid tumours criteria and obtained from
patient’s radiology reports. Patient’s date of death from any
cause (if present) or date of study completion (26/01/2017;
censored date) was recorded.
Body composition assessment
Computed tomography images, taken as part of routine pa-
tient care, were used to assess body composition as previ-
ously described.29 The third lumbar vertebrae were chosen
as the standard landmark, and two consecutive transverse
CT images where both transverse processes were clearly vis-
ible were analysed using OsiriX software version 4.1.1
(Pixmeo, Geneva, Switzerland), and the average result was
reported. Different tissue compartments were manually
outlined, and segmentation of the skeletal muscle and adi-
pose tissue was based on Hounsﬁeld unit (HU) thresholds
(29 to +150 HU and 30 to 190, respectively).30 Skeletal
muscle area (SMA) (cm2) and adipose tissue area (ATA)
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(cm2) were automatically calculated by summing tissue pixels
and multiplying by pixel surface area after applying HU thresh-
olds. SMA and ATA were normalized for stature to compute
the skeletal muscle index (SMI) and adipose tissue index
(ATI) in cm2/m2, respectively. Mean MA in HU was reported
for the entire skeletal muscle area at the third lumbar verte-
brae. Anonymized CT images were analysed by one trained
study assessor who was blinded to the order of images. Pre-
treatment images were taken prior to treatment administra-
tion (median 40 days; IQR 61 to 24 days). The median duration
between scans was 118 days (IQR 92 to 158 days). To account
for variation in the exact duration of scan intervals, changes in
tissue are expressed as change/100 days.
Estimates of whole body fat mass (FM) and fat free mass
(FFM) were calculated using published regression equations.31
To estimate total body skeletal muscle mass, the regression
equation of Shen et al. was used.32 Changes are expressed as
losses or gains of >1 kg of skeletal muscle mass (SMM) or
FM on a whole body basis. It has previously been shown that
1 kg of skeletal muscle is associated with physical function
(i.e. muscle strength)33 and this cut point has been used to in-
vestigate signiﬁcant changes in muscle mass throughout can-
cer disease trajectory previously.23,27,34 Sarcopenia and low
MA were deﬁned according to pre-published cut points;
sarcopenia was deﬁned as a SMI <43 cm2/m2 in men with a
BMI <25 kg/m2, <53 cm2/m2 in men with a BMI ≥25 kg/m2,
and <41 cm2/m2 in women. Low MA was deﬁned as a mean
attenuation <41 HU in patients with a BMI <25 kg/m2 and
<33 HU in those with a BMI ≥25 kg/m2.15
Statistical analysis
Statistical analysis was completed using SPSS (version 21.0,
SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± SD
or median [IQR] where appropriate. Comparisons between
groups of patients were assessed using chi-squared test for cat-
egorical variables and unpaired t-tests and Mann–Whitney U-
tests to test for differences continuous variables. Paired t-tests
were used to assess changes in body composition. The
McNemar’s test was to test for signiﬁcances in paired categor-
ical data. Variables that had signiﬁcance of P ≤ 0.25 on univar-
iate analysis or had clinical relevance were eligible for inclusion
in multivariable analysis. Survival curves were constructed
using the Kaplan–Meier technique, and log-rank test was used
to compare survival between groups of patients. Survival was
measured from the date of the baseline (pre-treatment) CT im-
age until the date of death or censored date (study comple-
tion). At the time of censoring, 88 of the 225 patients (39.1%)
were still alive. Median follow-up time for these patients was
18.06 months [IQR 11.0 to 34.8 months]. Cox proportional haz-
ard analyses were used to estimate adjusted hazard ratios (HR)
with 95% conﬁdence intervals (CI) calculated. All P values were
two-sided, and the level of signiﬁcance was P < 0.05.
Results
Participants
A total of 243 patients with a foregut tumour were enrolled
in the study. Patients were excluded if they lacked an
evaluable baseline CT image (n = 18). Therefore, 225 patients
were included. MA analysis was carried out on all patients
with a contrast enhanced CT image (n = 202).
Patient characteristics
Baseline characteristics are presented in Table 1. The majority
of patients were male (67%), with a median age of 66 years
(IQR 36 to 82 years). Oesophageal cancer was most prevalent
(44%), and 51% of patients had stage IV disease. All patients
were receiving standard systemic chemotherapy (Table S1).
Anthropometry and body composition
Baseline anthropometric and nutritional characteristics are
presented in Table 2. In brief, the majority of the cohort was
overweight/obese (52.4%); however, 62% met the criteria
for CC, 40% were sarcopenic, and 49% had low MA. Cachexia
and sarcopenia were most prevalent in patients with
pancreatic cancer (71% and 47%, respectively) (Figure S1).
Table 1 Demographic and clinical characteristics of patients included in
this study
Total n = 225
Age and median (range) 65.6 (35.8–83.4)
Male 150 (66.7)
Current smoker, n (%) 38 (16.9)
Current drinker, n (%) 94 (41.8)
Tumour location, n (%)
Gastro-oesophageal 138 (61.3)
Oesophaeal and GO junction 99 (44.0)
Gastric 39 (17.3)
Hepato pancreato-biliary 87 (38.7)
Pancreatic 55 (24.4)
Cholangiocarcinoma 18 (8.0)
Gallbladder 10 (4.4)
Liver 4 (1.8)
Tumour stage, n (%)
I 7 (3.1)
II 40 (18.2)
III 62 (27.6)
IV 116 (51.1)
ECOG, n (%)
0–1 176 (78.2)
>2 49 (22.7)
Chemotherapy (±radiotherapy) received, n (%)
Palliative 126 (56.0)
Deﬁnitive chemorads 14 (6.2)
Neoadjuvant 54 (24.0)
Adjuvant 31 (13.8)
ECOG, Eastern CooperativeOncologyGroup; GO,Gastro-oesophageal.
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More women were sarcopenic (64% vs. 28%, P < 0.001)
and had low MA (63% vs. 42%, P = 0.006) compared with
men. CC, sarcopenia, and low MA were present in all BMI
categories, in fact, in those with a BMI >25 kg/m2, 72% had
CC, 41% had sarcopenia, and 56% had low MA.
Patients with sarcopenia had lower BMI (23.9 vs. 25.8 kg/
m2, P = 0.001) and, as expected, had lower SMA (men 169.4
vs. 144.8 cm2, P < 0.001; women 97.8 vs. 118.7 cm2,
P < 0.001), SMI (men 46.9 vs. 56.0 cm2/m2, P < 0.001;
women 36.9 vs. 47.2 cm2/m2, P < 0.001), and FFM (men
49.5 vs. 56.9 kg, P < 0.001; women 35.4 vs. 41.7 kg,
P < 0.001). Female patients with sarcopenia had a lower
ATA (366.2 vs. 254.1 cm2, P = 0.004), ATI (146.3 vs.
95.7 cm2/m2, P = 0.001), and FM (26.6 vs. 21.9 kg,
P = 0.004), and this was not observed in male patients. Pa-
tients with sarcopenia did not differ in age (64.8 vs.
63.9 years, P = 0.510) and had similar clinical features to
non-sarcopenic patients.
Longitudinal changes in body composition
Longitudinal changes in body composition were assessed in a
subset of patients who had a repeat CT image taken as part
of their medical management (n = 163; 104 men and 59
women). The changes are presented in Table 3. Changes in
overall body weight (kg) were not recorded.
On average, patients lost 6.1 cm2 (95% CI: 7.7 to
4.5 cm2, P < 0.001) of SMA per 100 days, corresponding
to 1.0 kg of SMM and 2.0 kg of FFM on a whole body ba-
sis. Men lost more SMA than women [8.5 cm2 (1.5 kg of
SMM)/100 days vs. 1.8 cm2 (0.3 kg SMM)/100 days,
P < 0.001], amounting to a relative rate of loss of 5.0%
vs. 1.8% per 100 days (P = 0.002). Patients without
sarcopenia (at baseline) lost more SMA [8.9 cm2 (1.5 kg
SMM) vs. 2.0 cm2 (0.3 kg SMM)/100 days, P < 0.001]
and FFM (4.9 vs. 1.0 kg/100 days, P < 0.001), compared
with sarcopenic patients. The prevalence of sarcopenia in-
creased from 40.5% (66 out of 163) at baseline to 49.1%
(80 out of 163) at the time of the second scan
(P = 0.016). Changes in skeletal muscle did not signiﬁcantly
differ between cancer types (all P = NS). Patients experi-
enced signiﬁcant losses in ATA [17.31 cm2/100 days
(95% CI: 28.07 to 6.54), P = 0.002], equivalent to
0.73 kg/100 days (95% CI: 1.18 to 0.27, P = 0.002) on
a whole body basis. MA decreased by 0.84 HU (95% CI:
1.59 to 0.08 HU, P = 0.031) per 100 days. Changes in
MA and measures of adiposity did not signiﬁcantly differ
between gender, cancer type, or the presence of
sarcopenia (all P = NS).
Mean losses of muscle and adipose tissue obscure the fact
that, in some instances, muscle and adipose tissue was gained
or remained stable. The ranges of SMM change (6.2 to
4.6 kg/100 days) and FM change (7.7 to 5.6 kg/100 days)
are displayed in Figure 1A and 1B, respectively. Overall,
45.4% of patients lost SMM, while 46% remained muscle sta-
ble (±1 kg). It is important to note that 23.9% of patients that
lost >1 kg of SMM had a concurrent gain of >1 kg of FM.
Table 2 Anthropometric and nutritional status characteristics of patients according to gender, values expressed as mean (standard deviation), unless
stated otherwise
Characteristic Men, n = 150 Women, n = 75 Total, n = 225 P value
Weight (kg) 77.9 (12.9) 62.7 (13.6) 72.8 (14.9) <0.001
Height (m) 1.75 (0.07) 1.61 (0.08) 1.7 (0.09) <0.001
BMI (kg/m2), n (%) 25.5 (3.9) 24.1 (4.9) 25.1 (4.3) 0.024
Underweight (≤18.5) 8 (5.3) 9 (12.0) 17 (7.6) 0.129
Normal (18.5–24.9) 56 (37.3) 34 (37.3) 90 (40.0) 0.312
Overweight (25–29.9) 66 (44.0) 22 (29.3) 88 (39.1) 0.048
Obese (≥30.0) 20 (13.3) 10 (13.3) 30 (13.3) 1.00
Cachexia, n (%) 91 (60.7) 48 (64.0) 139 (61.8) 0.734
Muscle parameters
Skeletal muscle area (cm2) 162.5 (25.2) 105.3 (15.2) 143.5 (35.0) <0.001
Skeletal muscle index (cm2/m2) 53.5 (8.3) 40.6 (5.9) 49.2 (9.7) <0.001
Sarcopenia, n (%) 42 (28.0) 48 (64.0) 90 (40.0) <0.001
Estimated FFM (kg)a 54.8 (7.6) 37.6 (4.5) 49.1 (10.5) <0.001
Estimated SMM (kg)a 30.3 (4.34) 20.41 (2.61) 26.99 (6.05) <0.001
Muscle attenuation (HU)b 37.5 (7.3) 35.6 (7.6) 36.8 (7.5) 0.080
Low muscle attenuation, n (%)b 55 (42.0) 45 (63.4) 100 (49.5) 0.006
Fat parameters
Adipose tissue area (cm2) 346.1 (165.5) 293.6 (160.0) 328.7 (165.2) 0.028
Adipose tissue index (cm2/m2) 114.2 (54.6) 113.6 (63.0) 113.9 (57.4) 0.942
Estimated FM (kg)a 25.7 (6.9) 23.5 (6.7) 25.0 (6.9) 0.027
BMI, body mass index; FM, fat mass; FFM, fat free mass; HU, Hounsﬁeld units; kg, kilogram; SD, standard deviation; SMM, skeletal muscle
mass.
aEstimated kilograms of FFM and FM are calculated from regression equations reported by Mourtzakis et al.31 and estimated kilograms of
SMM are calculated from regression equations reported by Shen et al.32
bMuscle attenuation analysis based on 202 patients (131 men and 71 women).
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Palliative vs. neoadjuvant chemotherapy
Changes in SMA, FFM, and SMM per 100 days varied signiﬁ-
cantly between chemotherapy types [palliative (n = 89), de-
ﬁnitive chemo-radiotherapy (n = 3), neoadjuvant (n = 47),
and adjuvant (n = 24)] (P < 0.001). The signiﬁcant differences
were observed among those treated with palliative and neo-
adjuvant chemotherapy (NACT) (Table 4). Patients treated
with NACT experienced greater losses in SMA, FFM, and
SMM compared with patients treated with palliative chemo-
therapy. No difference was observed in changes of ATA, FM,
or MA between chemotherapy types. Patients treated with
palliative and NACT did not signiﬁcantly differ in terms of
age, gender, or body composition at baseline.
Response to treatment and changes in body
composition
Response to treatment was evaluated in 157 of the 163 pa-
tients. Of these, 56 patients (36%) responded to chemother-
apy, while 62 (39%) progressed and 39 (25%) had stable
disease. Overall, no difference was observed in changes in
body composition parameters and response to treatment.
However, within those treated with NACT, patients who
responded (23/45 patients) to treatment lost less muscle
(1.4 vs. 2.6 kg of SMM/100 days, P = 0.090; 4.0% vs.
8.7% of SMA/100 days, P = 0.034) and gained adipose tis-
sue (+0.7 vs. 1.2 kg of FM/100 days, P = 0.017; +5.4% vs.
10.8% of ATA/100 days, P = 0.019) compared with those
who did not respond.
Body composition and survival
Median overall survival (OS) for the entire cohort was
15.7 months (95% CI: 14.0 to 17.4 months). Patients with
gastro-oesophageal cancer had a signiﬁcantly longer survival
than those with HPB cancer (19.7 vs. 13.5 months, log-rank
P < 0.001). As expected, patients treated with palliative che-
motherapy had a signiﬁcantly shorter OS compared with
those receiving treatment with a curative intent [11.7 months
(95% CI: 9.9 to 13.5) vs. 36.9 months (95% CI: 18.7 to 55.2),
log-rank P < 0.001].
To examine the effect of relative muscle loss on survival,
quartiles of muscle change were devised. No effect on sur-
vival was observed when the whole cohort was examined to-
gether or in those treated with curative intent; however,
within this group, a large proportion of cases was censored
(60%). Conversely, in patients treated with palliative chemo-
therapy [n = 89; 23 (26%) censored], survival curves were sig-
niﬁcantly different across quartiles of %SMA change/100 days
(log-rank P = 0.031). A median OS of 15.9, 15.7, 12.2, and
7.9 months was observed for group 1 [muscle gain
(≥0.85%/100 days)], group 2 [stable/minor muscle loss
(<0.85% to 2.35%/100 days)], group 3 [muscle loss
(2.35 to 6.0%/100 days)], and group 4 (highest muscle
loss >6.0%/100 days), respectively. Patients with a muscle
loss of >6.0%/100 days (group 4; highest muscle loss) had
signiﬁcantly lower OS compared with those with a muscle
loss ≤6.0%/100 days [7.9 months (95% CI: 6.7 to 9.1) vs.
15.6 months (95% CI: 13.3 to 17.9), respectively, (log rank;
P = 0.006)] (Figure 2). On multivariate analysis, muscle loss
of ≥6.0% remained independently associated with shorter
survival [HR: 2.66, (95% CI: 1.42 to 4.97), P = 0.002] (Table 5).
Neither sarcopenia nor low MA at baseline was associated
with shorter OS. Foregut cancer patients with CC had a
shorter median survival [15.1 months (95% CI: 13.1 to
17.1)] compared with patients without CC [17.5 months
(95% CI: 12.5 to 22.6), log rank P = 0.035; univariate analysis
HR: 1.46 (95% CI: 1.03 to 2.09), P = 0.036]. However, after ac-
counting for known prognostic covariates in a multivariate
model (age, gender, cancer type, cancer stage, and the
Table 3 Change in skeletal muscle and adipose tissue area (cm2) per 100 days according to cancer type
Tissue
Change per 100 days Relative change per 100 days (%)
Mean 95% CI P Mean 95% CI P
Skeletal muscle area (cm2)
All foregut cancers (n = 163) 6.1 7.7 to 4.4 <0.001 3.9 4.9 to 2.8 <0.001
Gastro-oesophageal, (n = 99) 7.7 9.9 to 5.5 <0.001 4.8 6.2 to 3.5 <0.001
Gastric, (n = 27) 7.9 12.2 to 3.7 0.001 4.2 7.1 to 1.3 0.006
Oesophageal, (n = 72) 7.6 10.3 to 4.9 <0.001 5.1 6.7 to 3.5 <0.001
Hepato pancreato-biliary, (n = 64) 3.6 5.8 to 1.4 0.002 2.5 4.1 to 0.8 0.004
Pancreatic, (n = 40) 4.0 7.0 to 1.1 0.009 2.9 5.2 to 0.8 0.010
Biliary (gallbladder, liver, and bile duct), (n = 24) 2.8 6.2 to 0.7 0.111 1.6 4.2 to 1.0 0.212
Total adipose tissue area (cm2)
All foregut cancers (n = 154) 17.3 28.1 to 6.5 0.002 3.5 7.7 to 0.7 0.105
Gastro-oesophageal, (n = 93) 12.7 26.6 to 1.2 0.074 1.8 7.6 to 4.0 0.533
Gastric, (n = 26) 17.0 44.1 to 10.0 0.207 0.1 15.9 to 16.0 0.994
Oesophageal, (n = 67) 11.0 27.7 to 5.6 0.191 2.6 8.0 to 2.9 0.357
Hepato pancreato-biliary, (n = 61) 24.3 41.6 to 7.0 0.007 6.0 12.3 to 0.1 0.054
Pancreatic, (n = 39) 33.5 55.2 to 11.9 0.003 8.8 16.4 to 1.2 0.024
Biliary (gallbladder, liver, and bile duct), (n = 22) 8.0 38.0 to 21.9 0.583 1.1 12.0 to 9.8 0.837
CI, conﬁdence interval.
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Figure 1 (A) Change in skeletal muscle mass (SMM) (kg) per 100 days in patients with cancers of the foregut (n = 163) and (B) change in fat mass (FM)
(kg) per 100 days in patients with cancers of the foregut (n = 154).
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Table 4 Change in measures of muscle mass in patients treated with palliative vs. neoadjuvant chemotherapy. All values expressed as mean change
(95% CI) per 100 days
Palliative chemotherapy (n = 89) Neoadjuvant chemotherapy (n = 47) Mean difference P value
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Δ SMA (cm2) 4.7 (6.6 to 2.8) 11.3 (14.7 to 7.96) 6.6 (10.2 to 3.1) <0.001
Δ SMA (%) 2.8 (4.2 to 1.4) 7.3 (9.1 to 5.4) 4.5 (6.8 to 2.1) <0.001
Δ FFM (kg) 1.4 (3.7 to 1.3) 3.4 (4.4 to 2.4) 2.0 (3.1 to 0.9) <0.001
Δ FFM (%) 2.5 (3.7 to 1.3) 6.3 (8.4 to 4.2) 3.8 (6.0 to 1.6) 0.001
Δ SMM (kg) 0.8 (1.1 to 0.5) 1.9 (2.4 to 1.4) 1.2 (1.8 to 0.5) <0.001
Δ SMM (%) 2.6 (3.9 to 1.4) 6.6 (8.8 to 4.5) 4.0 (6.3 to 1.7) 0.001
All changes in measures of SMA (cm2 and %), FFM (cm2 and %), and SMM (cm2 and %) listed within groups have a P < 0.001. CI,
conﬁdence interval; FFM, fat free mass; SMA, skeletal muscle area; SMM, skeletal muscle mass.
6 L.E. Daly et al.
Journal of Cachexia, Sarcopenia and Muscle 2018
DOI: 10.1002/jcsm.12267
Eastern Oncology Cooperative Group), CC did not remain sig-
niﬁcant (HR: 1.33 (95% CI: 0.93 to 1.90), P = 0.124).
Discussion
Our study details the changes in body composition in foregut
cancer patients undergoing chemotherapy, highlighting the
magnitude of muscle and adipose tissue wasting over time,
particularly in patients treated with NACT. We describe the
adverse prognostic impact of muscle loss on survival in pa-
tients treated with palliative chemotherapy.
Our data underscore the critical importance of muscle tis-
sue assessment in patients with foregut cancer undergoing
chemotherapy. High rates of cachexia (62%), sarcopenia
(40%), and low MA (49%) were observed (despite a high
BMI), and this is in line with previous research.8,19,35
Compounding this is the ongoing loss of muscle patients ex-
perience undergoing chemotherapy, with a relative muscle
loss of 3.9%/100 days (P < 0.001). This is considerably
Figure 2 Kaplan–Meier curves for groups of relative muscle change (% change skeletal muscle area/100 days). Patients with a muscle loss of ≥6.0%/
100 days (group four, highest amount of muscle loss) had signiﬁcantly lower overall survival compared with those with a muscle loss <6.0%/100 days
(groups one to three; minor muscle loss/stable or gain). Censored cases are indicated by +.
Log rank: p=0.006
Table 5 Estimated crude and adjusted HRs for factors thought to be associated with overall survival in patients receiving palliative chemotherapy
(n = 89)
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender (ref male) 1.00 (0.61–1.64) 0.998 0.73 (0.39–1.38) 0.333
Age >65.6 years 0.76 (0.46–1.25) 0.281 0.77 (0.44–1.33) 0.342
Current smoker 1.29 (0.74–2.22) 0.374
HPB cancer (ref GO cancer) 1.83 (1.11–3.01) 0.018 2.02 (1.09–3.76) 0.026
ECOG PS >2 (ref 0–1) 1.75 (0.95–3.24) 0.074 2.21 (1.12–4.26) 0.017
BMI <25 kg/m2 (ref >25 kg/m2) 1.47 (0.90–2.41) 0.128 1.64 (0.98–2.74) 0.062
Cachexia 0.81 (0.49–1.33) 0.397
Sarcopenia 1.12 (0.69–1.83) 0.649
Low MA 1.12 (0.67–1.85) 0.667
Muscle loss >6% (ref <6%) 2.11 (1.22–3.67) 0.008 2.66 (1.42–4.97) 0.002
BMI, body mass index; CI, conﬁdence interval; ECOG PS, the Eastern Oncology Cooperative Group performance score; GO, gastro-oesoph-
ageal; HPB, hepato-pancreato-biliary; HR, hazard ratio; MA, muscle attenuation; ref, reference.
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greater compared with ageing healthy adults, who typically
lose muscle at a rate of 1–1.4% per year.36,37 However, the
mean rate of muscle loss is comparable with that observed
in advanced pancreatic cancer patients (3.1 ± 12%/
100 days) receiving palliative care (n = 44)25 and a recent re-
port from our own group in metastatic melanoma patients
(3.3 ± 5.8%/100 days) receiving immunotherapy
(n = 59).38 Higher rates of muscle loss were observed in pa-
tients treated with NACT (7.3%/100 days), similar to those
observed in ovarian cancer patients (5.2 ± 9.8%/100 days)
undergoing NACT (n = 123).28 Other studies have reported
signiﬁcant reductions in skeletal muscle in a variety of cancer
types8,24,26,39 but failed to report these as a change/100 days,
which makes it difﬁcult to compare with our cohort given the
heterogeneity in the interval between scans.
We reported herein that foregut cancer patients receiving
palliative chemotherapy with a muscle loss >6%/100 days
were at a signiﬁcantly increased risk of mortality. The in-
creased mortality risk may be attributed to a more aggressive
tumour proﬁle in patients with muscle loss. Alternatively,
patients with muscle loss may experience a higher degree
of cachexia. Cachexia induces systemic inﬂammation and
metabolic alterations, which in combination with a decrease
in body protein stores may explain the poor prognosis in
these patients. Loss of muscle mass may also affect the toler-
ability of systemic chemotherapy. Foregut cancer patients
with low muscle mass are more prone to severe treatment-
related toxicities, resulting in fewer completed cycles of che-
motherapy.7,14,39 This may result in inferior disease control
and adversely impact on survival.
Our results corroborate the ﬁndings in metastatic colorec-
tal cancer patients (n = 63) and metastatic melanoma patients
(n = 59), whereby a loss of muscle >9% over 3 months of che-
motherapy and >7.5%/100 days while undergoing immuno-
therapy, respectively, was independently associated with
reduced survival.21,38 Similarly, Miyamoto et al.26 reported a
muscle loss>5% during chemotherapy was signiﬁcantly asso-
ciated with poorer overall survival and progression free sur-
vival in unresectable colorectal cancer patients (n = 148). In
contrast to our ﬁndings, Tan et al.25 observed no signiﬁcant
difference in survival across tertiles of muscle loss in a small
cohort of advanced pancreatic cancer patients (n = 44). Of
note, patients in that study had a much poorer prognosis with
a median survival of 4 months, compared with a median sur-
vival of 12 months in the present study. Moreover, the second
CT scan was taken on average 95 days before death, indicating
that patients may have been entering the refractory-cachexia
phase. Therefore, the maintenance or gain of skeletal muscle
in that setting may have only limited clinical beneﬁt. In the
neoadjuvant setting, Rutten et al.28 reported that a loss of
muscle >2%/100 days was independently associated with re-
duced survival in ovarian cancer patients [HR: 1.77 (95% CI
1.018 to 3.088, P = 0.043)]. Within our cohort, the relationship
between the magnitude of muscle loss and mortality in
patients treated with NACT was difﬁcult to determine given
the large proportion of censored cases (60%) at the time of
analysis. However, it is possible that the impact of muscle loss
may vary with cancer diagnosis, treatment, and overall prog-
nosis. This has been observed in colorectal cancer patients;
sarcopenia was predictive of survival in patients undergoing
curative resection but not in patients with unresectable
disease receiving chemotherapy.26,40
Sarcopenia and lowMA at baseline were not associated with
reduced survival. This is in contrast to some10,15,25 but not all
research ﬁndings.8,16,21,24,41 This may be reﬂective of the fact
that sarcopenia (at one time point) is not a measure of actual
muscle loss and may be inﬂuenced by patients intrinsic level
of muscularity. Alternatively, this may be reﬂective of the valid-
ity of commonly used cut points (for SMI) to diagnose
sarcopenia. To date, no consensus exists on the optimal cut
points to deﬁne sarcopenia in patients with cancer. Many cut
points have been reported, which have been shown to vary
widely in male (36 to 55.4 cm2/m2) and female (29 to
42.1 cm2/m2) patients.42 Therefore, careful consideration
should be given to the choice of cut point to deﬁne sarcopenia.
Several factors inﬂuence patients muscularity (e.g. ethnicity,
age, gender, obesity, socio-economic factors, and dietary
habits), on which the cut point is dependant and should be
taken into account. Ideally, cut points for sarcopenia and low
MA would be ethnically speciﬁc; however, in the absence of
well-deﬁned and validated cut points derived from European
populations, we chose to use the cut points for sarcopenia
and low MA reported by Martin et al.15 These cut points were
devised from the largest available data set to date and are BMI
speciﬁc. They were devised from a heterogenous group of pa-
tients in terms of cancer site, stage, and performance status,
similar to our cohort. In addition, they have been validated to
predict survival in a number of external cohorts.43,44 However,
large international (and European speciﬁc) data repositories
are needed to further address this issue and deﬁne the most
robust diagnostic criteria for sarcopenia in patients with cancer.
Loss of muscle in this cohort is likely multifactorial. It may
be reﬂective of advancing disease, with the release of pro-
inﬂammatory cytokines associated with the underlying malig-
nancy promotingmuscle protein catabolism.45 In line with this,
we noted that response to treatment and reduction in tumour
burden was associated with less muscle loss in patients treated
with NACT, and similar results have been reported in gastric39
and lung cancer.24 Reduced physical activity would undoubt-
edly contribute to muscle loss, and studies have shown that
cancer patients are physically inactive.46 Muscle loss may also
be as a consequence of some cancer directed therapies.47
Our ﬁndings highlight the critical need for effective inter-
ventions to address muscle degradation and to negate the
adverse outcomes associated with the phenomenon. To date,
no pharmacotherapies have been approved for the treatment
of the cancer cachexia syndrome, although phases II and III
trials have yielded encouraging results.48,49 It has been
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proposed that multimodal interventions are required to ad-
dress the multifactorial syndrome.50,51 One such intervention
that is currently under investigation is the multimodal
exercise/nutrition/anti-inﬂammatory treatment for cachexia
trial, whereby phase II studies have yielded encouraging re-
sults.52 The phase III trial (NCT02330926) is currently being
conducted across a number of international sites, the results
of which are eagerly awaited. Furthermore, future studies ex-
amining cachexia interventions should consider recruiting pa-
tients beyond those with weight loss/cachexia at baseline
(typical inclusion criteria of weight loss >5%). A study exam-
ining the inclusion criteria for cancer cachexia clinical trials
identiﬁed that 41% of patients excluded from the trial due
to insufﬁcient weight loss (<5%) had a skeletal muscle loss
>5% but had a concurrent gain of visceral adipose tissue.53
Similarly, within our study, 24% of patients with a muscle loss
(>1 kg) had a concurrent gain in fat mass (>1 kg), which can
often lead to no net change in body weight.
Despite the relatively large sample size, this study has
limitations. Patients were excluded if CT scans were not
available, which may result in selection bias. Measures of
food intake and physical activity were not collected in the
present study, which represent a limitation as both may in-
ﬂuence muscle mass and body composition, and particularly
its change within this study. In addition, muscle depletion is
only one aspect of functional depletion, and muscle func-
tion and strength were not measured in this study but
should be investigated further. Future studies must focus
on the aetiology of body composition change in patients
with cancer and determine if these changes are preventable
or reversible.
In conclusion, signiﬁcant muscle loss occurred in patients
with foregut cancers during chemotherapy, particularly in
those treated with NACT. In patients receiving palliative che-
motherapy, a muscle loss of 6% or more was independently
associated with poorer survival. The routine availability of
CT scans in oncology represents a unique and exploitable
opportunity to assess body composition change, identifying
those at nutritional risk and allowing earlier nutritional inter-
vention. Prevention of cancer cachexia and its associated
muscle loss have huge potential to improve patient focused
clinical outcomes; however, better treatment options are
sorely needed.
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